Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $4.70
Previous CloseN/A
Volume917.00
Average Volume (3M)25.64K
Market Cap
$634.52M
Enterprise Value$91.47M
Total Cash (Recent Filing)$96.56M
Total Debt (Recent Filing)$54.33M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Sep 25, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding139,151,280
10 Day Avg. Volume37,787
30 Day Avg. Volume25,638
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue9.95
Enterprise Value/Gross Profit9.95
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$18.50Price Target Upside312.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Phase III NATiV3 trial for lanifibranor has completed full enrollment and is on track to report Phase III top-line data, making it a compelling asset for partnering.
Competitive AdvantageLanifibranor is complementary when combined with GLP-1s and SGLT2 class drugs, which is significant since a large percentage of MASH patients also have T2D.
Financial StabilityThe company's previous funding concerns were resolved with a significant financing, making it an appealing asset with blockbuster potential.
Bears Say
Clinical Trial DesignThe 'double-hit' on primary endpoint will also likely to lead to a much lower placebo rate in the clinical trial.
Financial DependencyCompletion of enrollment in NATiV3 supports satisfaction of certain conditions related to the second tranche of approximately €116 million of structured financing.
Market CompetitionNo other developers have any investigational MASH agent with trials specifically designed to treat this patient group.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $4.70 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $634.52M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 25, 2025 which is in 32 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 26, 2025. The company reported -$1.818 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$1.259.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.63.
How many shares outstanding does Inventiva have?
Inventiva has 139,151,280 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.818 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.50 (312.95% Upside)
$18.50 (312.95% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.02%
12-Months-Change
Fundamentals
Return on Equity
344.74%
Trailing 12-Months
Asset Growth
60.83%
Trailing 12-Months
Company Description
Inventiva
Inventiva (IVA) is a clinical-stage biopharmaceutical company focused on the development of orally-available therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases with significant unmet medical needs. The company leverages its proprietary technology platform to develop novel small molecule drugs that target nuclear receptors, transcription factors, and epigenetic modulation.
IVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of lanifibranor, positive trial results, and a strong financial position bolstered by recent financing activities. However, challenges such as workforce reduction and decreased revenue were noted. The sentiment remains cautiously optimistic with strategic partnerships and governance strengthening, despite financial and operational challenges.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$18.50
▲(312.95% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.44% Other Institutional Investors
96.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---